CoChat

Invasive Saccharomyces Infection: A Comprehensive Review

Enache-Angoulvant, A., Hennequin, C. · 2005 · Clinical Infectious Diseases

The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Saccharomyces cerevisiae (also known as "baker's yeast" or "brewer's yeast") is mostly considered to be an occasional digestive commensal. However, since the 1990s, there have been a growing number of reports about its implication as an etiologic agent of invasive infection. A particular feature of such infections is their association with a probiotic preparation of Saccharomyces boulardii (a subtype of S. cerevisiae) for treatment various diarrheal disorders. METHODS: We collected published case reports, through May 2005, of invasive Saccharomyces infection by use of a Medline query. Epidemiological and clinical charts and therapeutic strategies were analyzed. RESULTS: We found 92 cases of Saccharomyces invasive infection. Predisposing factors were similar to those of invasive candidiasis, with intravascular catheter and antibiotic therapy being the most frequent. Blood was the most frequent site of isolation (for 72 patients). S. boulardii accounted for 51.3% of fungemias and was exclusively isolated from blood. Compared with patients infected with S. cerevisiae, patients infected with S. boulardii were more frequently immunocompetent and had a better prognosis. Saccharomyces invasive infection was clinically indistinguishable from an invasive candidiasis. Overall, S. cerevisiae clinical isolates exhibited low susceptibility to amphotericin B and azole derivatives. However, global outcome was favorable in 62% of the cases. Treatment with intravenous amphotericin B and fluconazole, in combination with central vascular catheter removal, were effective therapeutic options. CONCLUSION: Saccharomyces organisms should now be added to the growing list of emerging fungal pathogens. Special caution should be taken regarding the use of S. boulardii probiotic preparations.

Overview

Integrity signals

Registry

Crossref · 10.1086/497832

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 87 references

Research works printed but not linked: 9

  1. 2001, 11, 19
  2. Rubinstein, 1975, Medicine, 54, 331
  3. Eschete, 1980, Archives of Internal Medicine, 140, 1539, 10.1001/archinte.1980.00330220085032 · doi:10.1001/archinte.1980.00330220085032
  4. 1997, Bulletin de la Soci t de pathologie exotique (1990), 90, 307
  5. Pavese, 1999, Pathologie-biologie, 47, 579
  6. Feld, 1982, The Journal of Rheumatology, 9, 637
  7. Kirsch, 1999, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 34, 229
  8. Zunic, 1991, Th rapie, 46, 498
  9. Pletincx, 1995, Journal of pediatric gastroenterology and nutrition, 21, 113, 10.1097/00005176-199507000-00022 · doi:10.1097/00005176-199507000-00022 · Paper page

Cited by

See all 369

Metadata

Authors
Enache-Angoulvant, A., & Hennequin, C.
Affiliations
Hôpital Tenon (FR)
Corresponding author
Hennequin, C.
Venue
Clinical Infectious Diseases
Published
2005-12-01
Volume
41
Issue
11
Pages
1559-1568
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2168407031
Cited by
369
References
88
Citations by year
2026: 12 · 2025: 13 · 2024: 10 · 2023: 17 · 2022: 14 · 2021: 17 · 2020: 24 · 2019: 19 · 2018: 23 · 2017: 34 · 2016: 19 · 2015: 23 · 2014: 14 · 2013: 23 · 2012: 18
FWCI
1.95
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
Keywords
Saccharomyces cerevisiae, Saccharomyces boulardii, invasive candidiasis, fungemia, emerging fungal pathogens, amphotericin B susceptibility, fluconazole, central venous catheters, antibiotic therapy, immunocompetent patient
MeSH terms
Female, Humans, Male, Mycoses, Risk Factors, Saccharomyces

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.